belantamab mafodotin, pomalidomide, dexamethasone

Details

Key Milestones2
Call for patient/clinician input open07-Aug-24
Call for patient/clinician input closed07-Nov-24
Submission received19-Dec-24
Submission accepted10-Jan-25
Review initiated13-Jan-25
Draft CADTH review report(s) provided to sponsor for comment16-Apr-25
Deadline for sponsors comments29-Apr-25
CDA-AMC review report(s) and responses to comments provided to sponsor30-May-25
Expert committee meeting (initial)11-Jun-25
Draft recommendation issued to sponsor-
Draft recommendation posted for stakeholder feedback-
End of feedback period-

belantamab mafodotin, bortezomib, dexamethasone

Details

Key Milestones2
Call for patient/clinician input open07-Aug-24
Call for patient/clinician input closed07-Nov-24
Submission received19-Dec-24
Submission accepted10-Jan-25
Review initiated13-Jan-25
Draft CADTH review report(s) provided to sponsor for comment25-Apr-25
Deadline for sponsors comments06-May-25
CDA-AMC review report(s) and responses to comments provided to sponsor30-May-25
Expert committee meeting (initial)11-Jun-25
Draft recommendation issued to sponsor-
Draft recommendation posted for stakeholder feedback-
End of feedback period-

efanesoctocog alfa

Details

Key Milestones2
Call for patient/clinician input openAugust 07, 2024
Call for patient/clinician input closedSeptember 27, 2024
Submission receivedSeptember 18, 2024
Submission acceptedOctober 03, 2024
Review initiatedOctober 04, 2024
Draft CADTH review report(s) provided to sponsor for commentDecember 23, 2024
Deadline for sponsors commentsJanuary 09, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorFebruary 13, 2025
Expert committee meeting (initial)February 26, 2025
Draft recommendation issued to sponsorApril 09, 2025
Draft recommendation posted for stakeholder feedbackApril 17, 2025
End of feedback periodMay 05, 2025

trastuzumab deruxtecan

Details

Key Milestones2
Call for patient/clinician input open06-Aug-24
Call for patient/clinician input closed27-Sep-24
Submission received16-Sep-24
Clarification:

Eligible for consideration as a time-limited recommendation

Submission accepted01-Oct-24
Review initiated02-Oct-24
Draft CADTH review report(s) provided to sponsor for comment17-Dec-24
Deadline for sponsors comments03-Jan-25
CDA-AMC review report(s) and responses to comments provided to sponsor31-Jan-25
Expert committee meeting (initial)12-Feb-25
Draft recommendation issued to sponsor25-Feb-25
Draft recommendation posted for stakeholder feedback06-Mar-25
End of feedback period21-Mar-25
Final recommendation issued to sponsor and drug plans03-Apr-25
Final recommendation posted23-Apr-25
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)17-Apr-25
CDA-AMC review report(s) posted-

pembrolizumab

Details

Key Milestones2
Call for patient/clinician input open06-Aug-24
Call for patient/clinician input closed27-Sep-24
Submission received17-Sep-24
Submission accepted02-Oct-24
Review initiated03-Oct-24
Draft CADTH review report(s) provided to sponsor for comment18-Dec-24
Deadline for sponsors comments06-Jan-25
CDA-AMC review report(s) and responses to comments provided to sponsor31-Jan-25
Expert committee meeting (initial)12-Feb-25
Draft recommendation issued to sponsor26-Feb-25
Draft recommendation posted for stakeholder feedback06-Mar-25
End of feedback period21-Mar-25
Final recommendation issued to sponsor and drug plans04-Apr-25
Final recommendation posted24-Apr-25
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)22-Apr-25
CDA-AMC review report(s) posted-